Literature DB >> 19452570

Hepatitis C virus lymphotropism and peculiar immunological phenotype: effects on natural history and antiviral therapy.

Paolo Conca, Giovanni Tarantino.   

Abstract

Hepatitis C virus (HCV) has been recognized to be both a hepato- and lymphotropic virus. HCV lymphotropism represents an essential lap in the pathogenesis of virus-related autoimmune and lymphoproliferative disorders, ranging from clonal expansion of B-cells with organ- and non-organ-specific autoantibody production up to overt non-Hodgkin's lymphoma along a continuous step-by-step model of B-cell lymphomagenesis, where the intermediated mixed cryoglobulinemia could be considered as a stage of suppressible antigen-driven lymphoproliferation. HCV infection of lymphoid cells could set up privileged reservoirs able to interfere with the host viral clearance efficiency and may be implicated in viral recurrence after apparently successful antiviral therapy. The HCV long-lasting extrahepatic replicative state generates an abnormal systemic immunological response, easily detectable by searching simple laboratory and clinical parameters, mainly represented by vasculitis-like skin features and hypocomplementemia. The presence or absence of this hypersensitivity pattern seems to correlate with the antiviral response and could be identified as a novel immunological cofactor. Further research is required to fully verify the real impact on therapeutic choice/regimen.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19452570      PMCID: PMC2684594          DOI: 10.3748/wjg.15.2305

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  38 in total

Review 1.  Extrahepatic disease manifestations of HCV infection: some current issues.

Authors:  Vincent Agnello; Francesco G De Rosa
Journal:  J Hepatol       Date:  2004-02       Impact factor: 25.083

2.  Mixed cryoglobulinaemia in patients with chronic hepatitis C infection: prevalence, significance and relationship with different viral genotypes.

Authors:  J P Horcajada; M García-Bengoechea; G Cilla; P Etxaniz; E Cuadrado; J I Arenas
Journal:  Ann Med       Date:  1999-10       Impact factor: 4.709

3.  Prevalence and incidence of cryoglobulins in hepatitis C virus-related chronic hepatitis patients: a prospective study.

Authors:  Marcello Persico; Fedele Antonio De Marino; Giovanni Di Giacomo Russo; Eliana Persico; Aristide Morante; Bruno Palmentieri; Roberto Torella
Journal:  Am J Gastroenterol       Date:  2003-04       Impact factor: 10.864

4.  HCV replication in PBMC and its influence on interferon therapy.

Authors:  Guo-Zhong Gong; Li-Ying Lai; Yong-Fang Jiang; Yan He; Xian-Shi Su
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

5.  Impact of alpha interferon and ribavirin on the function of maturing dendritic cells.

Authors:  Eleanor Barnes; Mariolina Salio; Vincenzo Cerundolo; Joanne Medlin; Shona Murphy; Geoffrey Dusheiko; Paul Klenerman
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

6.  Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia.

Authors:  D Sansonno; G Lauletta; L Nisi; P Gatti; F Pesola; N Pansini; F Dammacco
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

7.  Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.

Authors:  Haruaki Shirakawa; Akihiro Matsumoto; Satoru Joshita; Michiharu Komatsu; Naoki Tanaka; Takeji Umemura; Tetsuya Ichijo; Kaname Yoshizawa; Kendo Kiyosawa; Eiji Tanaka
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

8.  Effects of antiviral therapy on the cellular immune response in acute hepatitis C.

Authors:  Fareed Rahman; Theo Heller; Yuji Sobao; Eishiro Mizukoshi; Michelina Nascimbeni; Harvey Alter; Steven Herrine; Jay Hoofnagle; T Jake Liang; Barbara Rehermann
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

9.  Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes.

Authors:  Keigo Machida; Kevin T-N Cheng; Vicky M-H Sung; Shigetaka Shimodaira; Karen L Lindsay; Alexandra M Levine; Ming-Yang Lai; Michael M C Lai
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-03       Impact factor: 11.205

10.  Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas.

Authors:  Anna Linda Zignego; Clodoveo Ferri; Francesca Giannelli; Carlo Giannini; Patrizio Caini; Monica Monti; Maria Eugenia Marrocchi; Elena Di Pietro; Giorgio La Villa; Giacomo Laffi; Paolo Gentilini
Journal:  Ann Intern Med       Date:  2002-10-01       Impact factor: 25.391

View more
  11 in total

1.  Hepatitis C virus inhibits DNA damage repair through reactive oxygen and nitrogen species and by interfering with the ATM-NBS1/Mre11/Rad50 DNA repair pathway in monocytes and hepatocytes.

Authors:  Keigo Machida; George McNamara; Kevin T-H Cheng; Jeffrey Huang; Chun-Hsiang Wang; Lucio Comai; Jing-Hsiung James Ou; Michael M C Lai
Journal:  J Immunol       Date:  2010-10-25       Impact factor: 5.422

2.  Hepatitis C virus infection and its rheumatologic implications.

Authors:  Zeynel A Sayiner; Uzma Haque; Mohammad U Malik; Ahmet Gurakar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-05

3.  Primary follicular lymphoma of the spleen incidentally found in a patient with alcohol- and hepatitis C-related liver cirrhosis.

Authors:  Ikuo Matsuda; Masaya Okada; Takayuki Inoue; Tazuko Tokugawa; Hiroyasu Ogawa; Seiichi Hirota
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  Shear wave elastography (SWE) of the spleen in patients with hepatitis B and C but without significant liver fibrosis.

Authors:  Aleksander Pawluś; Marcin Inglot; Mariusz Chabowski; Kinga Szymańska; Małgorzata Inglot; Mateusz Patyk; Joanna Słonina; Filipe Caseiro-Alves; Dariusz Janczak; Urszula Zaleska-Dorobisz
Journal:  Br J Radiol       Date:  2016-08-16       Impact factor: 3.039

5.  Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma.

Authors:  Jeff Hosry; Parag Mahale; Francesco Turturro; Roberto N Miranda; Minas P Economides; Bruno P Granwehr; Harrys A Torres
Journal:  Int J Cancer       Date:  2016-08-18       Impact factor: 7.396

6.  Hepatitis C virus cryoglobulinemia and non-hodgkin lymphoma.

Authors:  Zohreh Jadali
Journal:  Hepat Mon       Date:  2012-02-29       Impact factor: 0.660

7.  Hepatitis B or C virus infection and risk of non-Hodgkin lymphoma among solid organ transplant recipients.

Authors:  Lindsay M Morton; Todd M Gibson; Christina A Clarke; Charles F Lynch; Dennis D Weisenburger; Eric A Engels
Journal:  Haematologica       Date:  2014-02-21       Impact factor: 11.047

8.  A retrospective analysis of treatment outcomes in patients with hepatitis C related systemic vasculitis receiving intravenous methylprednisolone and cyclophosphamide.

Authors:  Amira A Shahin; Soha M El Desouky; Hania S Zayed
Journal:  Clin Rheumatol       Date:  2010-10-06       Impact factor: 3.650

9.  Successful and Safe Long-Term Standard Antiviral Therapy in a Patient with "Explosive" Immune Response in Course of HCV-Related Liver Cirrhosis.

Authors:  Paolo Conca; Giovanni Cafaro; Amalia De Renzo; Antonio Coppola; Ernesto Cimino; Giovanni Tarantino
Journal:  Int J Mol Sci       Date:  2015-06-19       Impact factor: 5.923

10.  Serum Biomarkers for Discrimination between Hepatitis C-Related Arthropathy and Early Rheumatoid Arthritis.

Authors:  Isabela Siloşi; Lidia Boldeanu; Viorel Biciuşcă; Maria Bogdan; Carmen Avramescu; Citto Taisescu; Vlad Padureanu; Mihail Virgil Boldeanu; Anica Dricu; Cristian Adrian Siloşi
Journal:  Int J Mol Sci       Date:  2017-06-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.